Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
University of California, San Diego
Merck Sharp & Dohme LLC
Washington University School of Medicine
Radiation Therapy Oncology Group
Boehringer Ingelheim
Varian, a Siemens Healthineers Company
I-Mab Biopharma US Limited
Incyte Corporation
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Thomas Jefferson University
University of Arkansas
Sanford Health
Massachusetts General Hospital
University of Wisconsin, Madison
Palleon Pharmaceuticals, Inc.
Incyte Corporation
MacroGenics
University of Michigan
The University of Texas Health Science Center at San Antonio
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
University of California, San Diego
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
University of Colorado, Denver
Hoffmann-La Roche
M.D. Anderson Cancer Center
Alume Biosciences, Inc.
VA Office of Research and Development
M.D. Anderson Cancer Center
GeoVax, Inc.
Wake Forest University Health Sciences
University of Colorado, Denver
University of Pittsburgh
Intensity Therapeutics, Inc.
City of Hope Medical Center
University of Pittsburgh
Royal Marsden NHS Foundation Trust
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
BeiGene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Abramson Cancer Center at Penn Medicine
UNC Lineberger Comprehensive Cancer Center